Portugal Cannabis Law

Portugal has been a significant player in the European medical cannabis market since 2018, when it licensed domestic cultivation and processing for medical and scientific purposes. INFARMED (the National Authority of Medicines and Health Products) oversees licensing under Decree-Law 8/2019. Portugal's Mediterranean climate, low labor costs, and EU membership make it a strategically important production jurisdiction for European medical cannabis supply chains.

Several Canadian LPs and European cannabis companies have established Portuguese cultivation facilities for EU-GMP compliant production targeting German, UK, and broader European markets. The EU-GMP certification pathway at INFARMED is one of the most straightforward in Europe, making Portugal a preferred jurisdiction for international operators seeking EU market access.

Bob Hoban has advised US investors and operators on Portuguese market entry, INFARMED licensing timelines, and the strategic positioning of Portugal-based production within European supply chain structures. Key advisory areas include Decree-Law 8/2019 compliance, EU-GMP certification pathways, and M&A involving Portuguese licensed producers.